KR20230004595A - 유방암 치료제 - Google Patents

유방암 치료제 Download PDF

Info

Publication number
KR20230004595A
KR20230004595A KR1020227039422A KR20227039422A KR20230004595A KR 20230004595 A KR20230004595 A KR 20230004595A KR 1020227039422 A KR1020227039422 A KR 1020227039422A KR 20227039422 A KR20227039422 A KR 20227039422A KR 20230004595 A KR20230004595 A KR 20230004595A
Authority
KR
South Korea
Prior art keywords
breast cancer
therapeutic agent
cdk4
estrogen receptor
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039422A
Other languages
English (en)
Korean (ko)
Inventor
교코 니시바타
사요 후쿠시마
사토시 가와노
사오리 미야노
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20230004595A publication Critical patent/KR20230004595A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227039422A 2020-04-17 2021-04-15 유방암 치료제 Pending KR20230004595A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-074386 2020-04-17
JP2020074386 2020-04-17
PCT/JP2021/015546 WO2021210636A1 (ja) 2020-04-17 2021-04-15 乳がん治療剤

Publications (1)

Publication Number Publication Date
KR20230004595A true KR20230004595A (ko) 2023-01-06

Family

ID=78084563

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039422A Pending KR20230004595A (ko) 2020-04-17 2021-04-15 유방암 치료제

Country Status (10)

Country Link
US (1) US20230149381A1 (https=)
EP (1) EP4122465A4 (https=)
JP (1) JPWO2021210636A1 (https=)
KR (1) KR20230004595A (https=)
CN (1) CN115397415A (https=)
AU (1) AU2021255084B2 (https=)
BR (1) BR112022020786A2 (https=)
CA (1) CA3180128A1 (https=)
MX (1) MX2022012934A (https=)
WO (1) WO2021210636A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
CN108367000A (zh) 2015-12-17 2018-08-03 卫材R&D管理有限公司 用于乳腺癌的治疗剂
AU2021315234A1 (en) * 2020-07-31 2023-01-19 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
KR20180015079A (ko) 2016-08-02 2018-02-12 다이요 유덴 가부시키가이샤 적층 세라믹 콘덴서
US20180303817A1 (en) 2015-12-17 2018-10-25 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
WO2018049233A1 (en) * 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
US20180303817A1 (en) 2015-12-17 2018-10-25 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
KR20180015079A (ko) 2016-08-02 2018-02-12 다이요 유덴 가부시키가이샤 적층 세라믹 콘덴서
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
[비특허문헌 1] Bottcher et al., Acta Oncologica, 2019, 58(2), 147-153.
[비특허문헌 2] Howell et al., Journal of Clinical Oncology, 2004, 22(9), 1605-1613.
[비특허문헌 3] Seki et al., In vivo, 2019, 33, 2037-2044.
[비특허문헌 4] Nayar et al., Nature Genetics, 2019, 51, 207-216.

Also Published As

Publication number Publication date
MX2022012934A (es) 2022-11-08
EP4122465A1 (en) 2023-01-25
US20230149381A1 (en) 2023-05-18
CA3180128A1 (en) 2021-10-21
BR112022020786A2 (pt) 2022-11-29
AU2021255084B2 (en) 2026-04-02
CN115397415A (zh) 2022-11-25
AU2021255084A1 (en) 2022-12-08
JPWO2021210636A1 (https=) 2021-10-21
WO2021210636A1 (ja) 2021-10-21
EP4122465A4 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
JP7745708B2 (ja) 癌を治療するための方法
KR20230004595A (ko) 유방암 치료제
CN105120868A (zh) 组合治疗
CA2851383A1 (en) 2 - carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases
AU2016271527A1 (en) PAC-1 combination therapy
EP1885187B1 (en) Methods for treating drug resistant cancer
CA2912346A1 (en) Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
CN112040944A (zh) 用于治疗癌症的组合
EP2263751B1 (en) Isoxazole compound for the treatment of gastrointestinal cancers
JP7142707B2 (ja) ピラゾロ［３，４－ｄ］ピリミジン化合物を有効成分とする治療剤
JP6205373B2 (ja) Ｎｄｇａ誘導体およびソラフェニブを含む組成物、ならびにがんの処置におけるこれらの使用
RU2847580C1 (ru) Терапевтическое средство против рака молочной железы
US20240269136A1 (en) Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
KR20160101027A (ko) 제약 조합물
EP4638443A1 (en) Transient receptor potential vanilloid 6 inhibitors
KR20230047056A (ko) 유방암 치료제
HK40041700A (en) Combinations for treating cancer
HK1110477B (en) Methods for treating drug resistant cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000